Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by β-adrenergic plus cholinergic agonists
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci201541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Nam Soo Joo und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Cystic Fibrosis Research Laboratory and. Hauptthemen laut MEDLINE: Mucociliary Clearance, Cystic Fibrosis, Adrenergic beta-Agonists, Cholinergic Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stanford University, University of Iowa, Center for AIDS Research, University of Alabama at Birmingham.
Abstract (Originalsprache)
Mucociliary clearance (MCC) is an innate defense mechanism that normally keeps airways clean but is dysfunctional in cystic fibrosis (CF) and other muco-obstructive pulmonary diseases. Previously we discovered that activating adenyl cyclase in combination with a cholinergic agonist increased MCC velocity (MCCV) synergistically in ex vivo WT and CF ferret and WT piglets. For what we believe is the first time, we show in vivo synergistic MCC using FDA approved β-adrenergic and cholinergic drugs delivered to the apical surface of WT and CF rats and a CF sheep model. Also, a single dose of the combined drugs is tolerated by humans. As for mechanisms, via ex vivo experiments, we show the combined agonists increased net fluid secretion mainly by stimulating gland secretion and by inhibiting surface absorption, consequently increasing airway surface liquid depth. They also increased net base secretion and increased ciliary beat frequency. Additional ex vivo and in vitro experiments show that the combined agonists had additive effects when combined with highly effective CF transmembrane conductance regulator modulator therapy. The synergistic increase in MCCV induced by this combination of agonists offers therapeutic potential for treating muco-obstructive pulmonary diseases, including CF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Cystic Fibrosis Research Laboratory and.
- Center for Excellence in Pulmonary Biology, Stanford University, Stanford, California, USA.
- Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
- Department of Medicine and.
- Innovative Medicines Accelerator Program, Stanford University, Stanford, California, USA.
Förderung
- Stanford University
- University of Iowa
- Center for AIDS Research, University of Alabama at Birmingham
Zitieren
APA
Joo, N. S., Birket, S. E., Keith, J. D., Ianowski, J. P., Luan, X., Spano, J., Bollyky, J. B., Dobry, M. N., Sabater, J. R., Williams, R. W., Engelhardt, J. F., Wine, J. J., & Milla, C. E. (2026). Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by β-adrenergic plus cholinergic agonists. Journal of Clinical Investigation. https://doi.org/10.1172/jci201541
Vancouver
Joo NS, Birket SE, Keith JD, Ianowski JP, Luan X, Spano J, et al. Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by β-adrenergic plus cholinergic agonists. Journal of Clinical Investigation. 2026. doi:10.1172/jci201541
BibTeX
@article{Joo2026,
author = {Joo, Nam Soo and Birket, Susan E and Keith, Johnathan D and Ianowski, Juan P and Luan, Xiaojie and Spano, Jacquelyn and Bollyky, Jennifer B and Dobry, Marissa N and Sabater, Juan R and Williams, Ryan W and Engelhardt, John F and Wine, Jeffrey J and Milla, Carlos E},
title = {Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by β-adrenergic plus cholinergic agonists},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci201541}
}
EUVIMED